Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)

NCT ID: NCT01366898

Last Updated: 2022-01-19

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2022-12-31

Brief Summary

The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL). Apply uniform treatment that enables a joint analysis of results strong enough to make conclusions on specific subgroups of patients (genotypic subtypes, particularly LAL Bcr/abl positive, phenotype, or strata of age or associated diseases). Provide results of a treatment to consider standard against which to compare the results of phase II trials of experimental drugs that undoubtedly will be activated in the coming years

Detailed Description

Prephase (days -5 to -1) Dexamethasone 10 mg/m2 bolus day IV for 5 days (-5 to -1). Supplementary treatment: hydration minimum 2000 ml/day, allopurinol 300 mg / day, gastric protection (as center), daily monitoring of blood glucose, daily monitoring of renal function. Intrathecal treatment (diagnosis and prophylactic) day -5: 12 mg were administered intrathecal methotrexate. The morphological study of the CSF will be defining initial CNS involvement by LAL. Although it is recommended immunophenotypic study of CSF, the definition of CNS involvement by LAL (and its therapeutic consequences) based on morphological observation of blasts in CSF cytocentrifuge.

Remission induction:

Tolerance prephase period can be used to establish the final indication of treatment (standard protocol or frail patients). Day 0 is free of treatment and is considered as +1 the first day of induction. The total duration of the induction is 30 days, consists of two phases (Phase I, days +1 to +14 and phase II, days +15 to +30). Mandatory testing is considered counting the percentage of blasts in peripheral blood +8 day of induction, a myelogram to day +14 to assess early response and a day +35 to assess the complete remission

(days +1 to +14)

• Vincristine (VCR) 1 mg (absolute dose) IV 1 and 8.
• Idarubicin (IDA): 10 mg (absolute dose) IV 1, 2, 8 and 9.
• Dexamethasone (DEX): 10 mg/m2 bolus days 1 and 2 IV, 8 to 11

days +15 to +30)

• cyclophosphamide (CFM): 300 mg / m 2 iV in 1 hour 15 to 17. (3 total doses).
• Cytarabine (ARAC): 60 mg / m 2 iV in 1 hour 16 to 19, 23 to 26. (8 total doses).
• Vincristine (VCR) 1 mg (absolute dose) iV 1 and 8.
• Idarubicin (IDA): 10 mg (absolute dose) iV 1, 2, 8 and 9.
• Dexamethasone (DEX): 10 mg/m2 bolus days 1 and 2 iV, 8 to 11

Consolidation:

Cycles 1, 3, 5 MTX: 1,000 mg/m2, IV infusion of 24 hours day 1 L-ASA. 10,000 IU / m 2 IV or IM Day 2 Cycles 2, 4, 6 ARAC: 1,000 mg/m2, IV in 3 hours on days 1, 3 and 5

Conditions

Acute Lymphoblastic Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Chemotherapy

Group Type: EXPERIMENTAL

Dexamethasona, Idarubicine, ARA-C, Methotrexate

Intervention Type: DRUG

Interventions

Dexamethasona, Idarubicine, ARA-C, Methotrexate

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Adults over 55 years diagnosed with ALL with chromosome Ph 'negative and naïve

Exclusion Criteria

1. L3 ALL with mature B phenotype or cytogenetic abnormalities ALL characteristics of Burkitt type (t [8, 14], t [2, 8], t [8, 22]).

2. Biphenotypic acute leukemias and bilinear

3. Acute undifferentiated leukemia

The criteria for exclusion from treatment (but not patient record) any of the following:

4. Patients with a history of severe and uncontrolled disease, including:

• Coronary artery disease, valvular or hypertensive heart disease.
• Chronic liver disease (active viral or alcoholic).
• Chronic respiratory failure.
• Renal failure not due to the ALL.
• Serious neurological disorder not due to the ALL. f. Improperly controlled diabetes.

5. General condition affected (grades 3 and 4 of the WHO scale, see Appendix II), not attributable to the LAL.

6. LAL chromosome Ph 'positive (must register even if you follow a specific protocol).

7. Lack of consent by the patient to use their medical records.

• Minimum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PETHEMA Foundation

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hospital Germans Trias i Pujol and all Hospital Pethema

Badalona, Barcelona, Spain

Site Status: RECRUITING

Countries

Spain

Facility Contacts

José Mª Ribera, Dr

Role: primary

jribera@iconcologia.net

References

Ribera JM, Garcia O, Fernandez-Abellan P, Lavilla E, Bernal MT, Gonzalez-Campos J, Brunet S, Monteserin MC, Montesinos P, Sarra J, Calbacho M, Alvarez-Larran A, Tormo M, Oriol A; PETHEMA Group. Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols. Br J Haematol. 2012 Nov;159(4):485-8. doi: 10.1111/bjh.12043. Epub 2012 Sep 12. No abstract available.

Reference Type: DERIVED

PMID: 22966847 (View on PubMed)

Related Links

https://www.fundacionpethema.es/

Related Info

Other Identifiers

LAL-07OLD

Identifier Type: -

Identifier Source: org_study_id